Forbes February 26, 2025
Eli Lilly is stockpiling massive quantities of an oral weight-loss drug that’s at least a year from launch, with total “pre-launch inventory” of nearly $550 million at Dec. 31, 2024, according to its 10-K financial statements released last week.
The unusual move represents a massive bet on a new once-daily pill for weight loss called orforglipron, at a time when GLP-1 drugs from Lilly and its competitor Novo Nordisk have taken the market by storm. Lilly’s tirzepatide drugs, Zepbound for obesity and Mounjaro for diabetes, both of which are administered by injection, accounted for $5.4 billion in revenue in the fourth quarter alone.
Orforglipron showed good results in a phase 2 trial published in the New England Journal of Medicine...
Today's Sponsors
Today's Sponsor